AR047263A1 - Proteina nmb1125 y su uso en formulaciones farmaceuticas - Google Patents
Proteina nmb1125 y su uso en formulaciones farmaceuticasInfo
- Publication number
- AR047263A1 AR047263A1 ARP040104481A ARP040104481A AR047263A1 AR 047263 A1 AR047263 A1 AR 047263A1 AR P040104481 A ARP040104481 A AR P040104481A AR P040104481 A ARP040104481 A AR P040104481A AR 047263 A1 AR047263 A1 AR 047263A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulations
- inducing
- nmb1125
- protein
- vaccine
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Uso de un antígeno vacunal aplicado de manera preventiva o terapéutica contra enfermedades bacterianas, virales, cancerosas, o de otro origen. El objetivo técnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro protector de las vacunas ya existentes y extenderlo contra diferentes patogenos. Para lograr este objetivo se aislo e identifico la proteína NMB1125 como componente de las preparaciones de membrana externa de Neissería meningitidis, capaz de inducir actividad bactericida. Adicionalmente, se clono y expreso el gen codificante para la proteína NMB1125, la cual se purifico evaluándose luego su inmunogenicidad en biomodelos animales. El secuenciamiento de genes homologos evidencio, por su elevado grado de conservacion, su alto valor como antígeno inductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. Las formulaciones resultantes son aplicables en la industria farmacéutica como formulaciones vacunales para uso humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030285A CU23237A1 (es) | 2003-12-03 | 2003-12-03 | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047263A1 true AR047263A1 (es) | 2006-01-11 |
Family
ID=40091628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104481A AR047263A1 (es) | 2003-12-03 | 2004-12-01 | Proteina nmb1125 y su uso en formulaciones farmaceuticas |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7691971B2 (es) |
| EP (1) | EP1693378B9 (es) |
| KR (1) | KR20060123759A (es) |
| CN (1) | CN1890260A (es) |
| AR (1) | AR047263A1 (es) |
| AT (1) | ATE444305T1 (es) |
| AU (1) | AU2004294376A1 (es) |
| BR (1) | BRPI0417309A (es) |
| CA (1) | CA2547317A1 (es) |
| CU (1) | CU23237A1 (es) |
| DE (1) | DE602004023419D1 (es) |
| ES (1) | ES2334138T3 (es) |
| NO (1) | NO20063020L (es) |
| NZ (1) | NZ547520A (es) |
| PL (1) | PL1693378T3 (es) |
| RU (1) | RU2336900C2 (es) |
| WO (1) | WO2005054281A2 (es) |
| ZA (1) | ZA200604556B (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22559A1 (es) * | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
| EP2261347A3 (en) * | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| AU780308B2 (en) | 1999-04-30 | 2005-03-17 | J. Craig Venter Institute, Inc. | Neisseria genomic sequences and methods of their use |
-
2003
- 2003-12-03 CU CU20030285A patent/CU23237A1/es unknown
-
2004
- 2004-12-01 AR ARP040104481A patent/AR047263A1/es unknown
- 2004-12-02 CN CNA2004800358779A patent/CN1890260A/zh active Pending
- 2004-12-02 WO PCT/CU2004/000015 patent/WO2005054281A2/es active Application Filing
- 2004-12-02 NZ NZ547520A patent/NZ547520A/xx unknown
- 2004-12-02 DE DE602004023419T patent/DE602004023419D1/de active Active
- 2004-12-02 BR BRPI0417309-0A patent/BRPI0417309A/pt not_active IP Right Cessation
- 2004-12-02 RU RU2006123434/13A patent/RU2336900C2/ru not_active IP Right Cessation
- 2004-12-02 AT AT04802607T patent/ATE444305T1/de not_active IP Right Cessation
- 2004-12-02 AU AU2004294376A patent/AU2004294376A1/en not_active Abandoned
- 2004-12-02 PL PL04802607T patent/PL1693378T3/pl unknown
- 2004-12-02 CA CA002547317A patent/CA2547317A1/en not_active Abandoned
- 2004-12-02 US US10/580,508 patent/US7691971B2/en not_active Expired - Fee Related
- 2004-12-02 ES ES04802607T patent/ES2334138T3/es active Active
- 2004-12-02 KR KR1020067010712A patent/KR20060123759A/ko not_active Application Discontinuation
- 2004-12-02 EP EP04802607A patent/EP1693378B9/en active Active
-
2006
- 2006-06-02 ZA ZA200604556A patent/ZA200604556B/xx unknown
- 2006-06-28 NO NO20063020A patent/NO20063020L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005054281A3 (es) | 2005-08-04 |
| AU2004294376A1 (en) | 2005-06-16 |
| PL1693378T3 (pl) | 2010-03-31 |
| DE602004023419D1 (de) | 2009-11-12 |
| EP1693378A2 (en) | 2006-08-23 |
| ATE444305T1 (de) | 2009-10-15 |
| ES2334138T3 (es) | 2010-03-05 |
| EP1693378B9 (en) | 2010-05-19 |
| NO20063020L (no) | 2006-09-01 |
| EP1693378B1 (en) | 2009-09-30 |
| CN1890260A (zh) | 2007-01-03 |
| RU2006123434A (ru) | 2008-01-10 |
| NZ547520A (en) | 2009-07-31 |
| US20070218000A1 (en) | 2007-09-20 |
| CU23237A1 (es) | 2007-09-26 |
| WO2005054281A2 (es) | 2005-06-16 |
| CA2547317A1 (en) | 2005-06-16 |
| BRPI0417309A (pt) | 2007-09-11 |
| KR20060123759A (ko) | 2006-12-04 |
| US7691971B2 (en) | 2010-04-06 |
| ZA200604556B (en) | 2007-03-28 |
| RU2336900C2 (ru) | 2008-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20111324A1 (no) | Rekombinant MVA-virus | |
| CY1118503T1 (el) | Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου | |
| CY1108875T1 (el) | Βλεννοπροσφυτικα σκευασματα που περιεχουν ξυλογλυκανη και ειναι χρησιμα σε ιατρικες συσκευες και σε φαρμακευτικα σκευασματα | |
| NO20054608L (no) | Influensavirusvaksine | |
| CY1117757T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
| CY1117872T1 (el) | Ολιγοπεπτιδικες ενωσεις και χρησεις εξ' aυτων | |
| TNSN07087A1 (en) | Stable liquid formulations of plasmid dna | |
| CY1105536T1 (el) | Η ΑΝΟΣΟΣΦΑΙΡΙΝΗ IgG3 ΣΑΝ ΔΕΙΚΤΗΣ ΠΡΟΣΤΑΣΙΑΣ ΕΝΑΝΤΙΑ ΣΤΙΣ ΜΟΛΥΣΜΑΤΙΚΕΣ ΙΪΚΕΣ ΑΣΘΕΝΕΙΕΣ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΗΣ | |
| BR112014001409A2 (pt) | métodos e composições para vacinação contra staphylococcus aureus | |
| BRPI0516963A (pt) | ácido nucleico, plasmìdeo, composição veterinária, vacina, métodos de proteção de aves domésticas de colonização por campylobacter e de proteção de um humano de infecção por campylobacter, uso de um ácido nucleico, um plasmìdeo, uma composição, ou uma vacina, e, alimento | |
| EA200801411A1 (ru) | Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях | |
| AR046937A1 (es) | Proteina nmb0928 y su uso en formulaciones farmaceuticas | |
| DE60336588D1 (de) | Verbesserte anthraximpfstoffe und abgabeverfahren | |
| NO20045587L (no) | Liposom vaksineformulering for finne-fisk | |
| AR047263A1 (es) | Proteina nmb1125 y su uso en formulaciones farmaceuticas | |
| CU23435A1 (es) | Proteína nmb2134 y su uso en formulaciones farmacéuticas | |
| CU23419A1 (es) | Proteína nmb0088 y su uso en formulaciones farmacéuticas | |
| BR112014007491A2 (pt) | sequências de aminoácidos para o controle de patógenos | |
| AR046921A1 (es) | Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes | |
| ES2073180T3 (es) | Vacuna adecuada para combatir la bacteria bordetella pertussis. | |
| CU23572A1 (es) | Composición farmacéutica que comprende la proteína nmb0938 | |
| DK1074266T3 (da) | Levende svækkede bakterier til anvendelse i vaccine | |
| WO2019059817A9 (en) | VACCINE BASED ON FUSION PROTEIN AND PLASMIDIC DNA | |
| AR060797A1 (es) | Composicion farmaceutica que comprende la proteina nmb0606 | |
| CU23528A1 (es) | Composición farmacéutica que comprende la proteína nmb0848 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |